Background/Aims: It is unclear whether 5-aminosalicylic acid (5-ASA) formulation is associated with treatment adherence in ulcerative colitis (UC). Thus, we aimed to investigate the adherence rate after switching from 5-ASA tablets to granules. Methods: This prospective study included 121 UC outpatients treated using 5-ASA tablets. They were grouped based on choice: Group 1 (continued with tablets) and Group 2 (switched to granules without regimen change). Group 2 was further divided into Group 3 (returned to tablets) and Group 4 (continued with granules). The patients completed a self-administered questionnaire regarding the treatment. The primary endpoint was change in adherence after switching to granules. Results: Seventy-nine patients continued with tablets, while 42 patients switched to granules. The adherence rate to the tablet was not significantly different between Group 1 and 2 before switching. In Group 2, switching to granules did not affect adherence. However, in Group 4, adherence significantly improved after switching to granules. Group 3 showed no significant change in adherence before and after switching from tablets. Full-time work and difficulty taking tablets were significant predictors of continuing with granules in Group 4. Conclusion: Patients who continued with 5-ASA granules showed significantly increased adherence, suggesting that patient-tailored drug formulations improved treatment adherence.

Higgins PD, Rubin DT, Kaulback K, Schoenfield PS, Kane SV: Systematic review: impact of non-adherence to 5-aminosalicylic acid products on the frequency and cost of ulcerative colitis flares. Aliment Pharmacol Ther 2009; 29: 247–257.
Kane S, Huo D, Aikens J, Hanauer S: Medication nonadherence and the outcomes of patients with quiescent ulcerative colitis. Am J Med 2003; 114: 39–43.
Kawakami A, Tanaka M, Nishigaki M, Naganuma M, Iwao Y, Hibi T, Sanada H, Yamamoto-Mitani N, Kazuma K: Relationship between non-adherence to aminosalicylate medication and the risk of clinical relapse among japanese patients with ulcerative colitis in clinical remission: a prospective cohort study. J Gastroenterol 2013; 48: 1006–1015.
Sonnenberg E, Siegmund B: Ulcerative colitis. Digestion 2016; 94: 181–185.
Shale MJ, Riley SA: Studies of compliance with delayed-release mesalazine therapy in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2003; 18: 191–198.
Mine S, Takeshima F, Akazawa Y, Matsushima K, Minami H, Yamaguchi N, Ohnita K, Isomoto H, Nakao K: Correlation of fecal markers with magnifying endoscopic stratification in patients with ulcerative colitis who are in clinical remission. Digestion 2018; 97: 82–89.
Khan N, Abbas AM, Koleva YN, Bazzano LA: Long-term mesalamine maintenance in ulcerative colitis: which is more important? Adherence or daily dose. Inflamm Bowel Dis 2013; 19: 1123–1129.
Hawthorne AB, Rubin G, Ghosh S: Review article: Medication non-adherence in ulcerative colitis – strategies to improve adherence with mesalazine and other maintenance therapies. Aliment Pharmacol Ther 2008; 27: 1157–1166.
Haynes RB, Ackloo E, Sahota N, McDonald HP, Yao X: Interventions for enhancing medication adherence. Cochrane Database Syst Rev 2008; 2:CD000011.
Desreumaux P, Ghosh S: Review article: Mode of action and delivery of 5-aminosalicylic acid – new evidence. Aliment Pharmacol Ther 2006; 24(suppl 1): 2–9.
Kane SV, Cohen RD, Aikens JE, Hanauer SB: Prevalence of nonadherence with maintenance mesalamine in quiescent ulcerative colitis. Am J Gastroenterol 2001; 96: 2929–2933.
Kane SV: Systematic review: adherence issues in the treatment of ulcerative colitis. Aliment Pharmacol Ther 2006; 23: 577–585.
Sewitch MJ, Abrahamowicz M, Barkun A, Bitton A, Wild GE, Cohen A, Dobkin PL: Patient nonadherence to medication in inflammatory bowel disease. Am J Gastroenterol 2003; 98: 1535–1544.
Becker U, Lindorff K, Andersen C, Ranlov PJ: Antacid treatment of duodenal ulcer. Acta Med Scand 1987; 221: 95–101.
Cramer JA, Mattson RH, Prevey ML, Scheyer RD, Ouellette VL: How often is medication taken as prescribed? A novel assessment technique. JAMA 1989; 261: 3273–3277.
Eisen SA, Miller DK, Woodward RS, Spitznagel E, Przybeck TR: The effect of prescribed daily dose frequency on patient medication compliance. Arch Intern Med 1990; 150: 1881–1884.
Farup PG: Compliance with anti-ulcer medication during short-term healing phase clinical trials. Aliment Pharmacol Ther 1992; 6: 179–186.
Evans L, Spelman M: The problem of non-compliance with drug therapy. Drugs 1983; 25: 63–76.
Watanabe M, Hanai H, Nishino H, Yokoyama T, Terada T, Suzuki Y: Comparison of QD and TID oral mesalazine for maintenance of remission in quiescent ulcerative colitis: A double-blind, double-dummy, randomized multicenter study. Inflamm Bowel Dis 2013; 19: 1681–1690.
Bohm SK, Kruis W: Long-term efficacy and safety of once-daily mesalazine granules for the treatment of active ulcerative colitis. Clin Exp Gastroenterol 2014; 7: 369–383.
Jackson CA, Clatworthy J, Robinson A, Horne R: Factors associated with non-adherence to oral medication for inflammatory bowel disease: a systematic review. Am J Gastroenterol 2010; 105: 525–539.
You do not currently have access to this content.